Cost-effectiveness of human papillomavirus vaccination in Belgium: Do not forget about cervical cancer screening

International Journal of Technology Assessment in Health Care

Volumn 25, Issue 2, 2009, Pages 161-170

  Thiry, Nancy ^a   De Laet, Chris ^a   Hulstaert, Frank ^a   Neyt, Mattias ^a   Huybrechts, Michel ^a   Cleemput, Irina ^a  

^a BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

Author keywords

Belgium; Cost effectiveness; Papillomavirus infections; Papillomavirus vaccines; Primary prevention

Indexed keywords

AFTER INITIATION; BELGIUM; CERVICAL CANCERS; ECONOMIC CONSEQUENCES; HUMAN PAPILLOMAVIRUS; MARKOV MODEL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRIMARY PREVENTION;

COST EFFECTIVENESS; MARKOV PROCESSES;

COSTS;

WART VIRUS VACCINE;

ADOLESCENT HEALTH; ARTICLE; BELGIUM; CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; POPULATION MODEL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; ADOLESCENT; ADULT; CHILD; COHORT ANALYSIS; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH CARE COST; MASS SCREENING; STATISTICS; UTERINE CERVIX TUMOR; UTILIZATION REVIEW;

ADOLESCENT; ADULT; BELGIUM; CHILD; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; MASS SCREENING; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 67549149220     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462309090217     Document Type: Article

References (46)

1. Anonymous. Sterftetafels 2001: Verwachte levensduur, sterftekans en overlevingskans. In: K.M.O. FOD Economie, Middenstand en Energie, editor. Brussels: Belgium; 2001.
2. Arveux P, Benard S, Bouee S, et al. Invasive cervical cancer treatment costs in France. Bull Cancer. 2007;94:219-224. (Pubitemid 46456117)
3. Belgian Cancer Registry Foundation. Stichting Kankerregister - Fondation Registre du Cancer. Brussels: Belgium; 2007.
4. Belgisch Centrum voor Farmacotherapeutische Informatie. Gecommentarieerd geneesmiddelenrepertorium. Ghent: Belgium; 2007.
5. Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care. 2008;24:10-19. (Pubitemid 351158538)
6. Beutels P, Van Damme P, Oosterhuis-Kafeja F. Effects and costs of pneumococcal conjugate vaccination of Belgian children. Health Technology Assessement (HTA). KCE reports. Brussels: Centre f́ed́eral d'expertise des soins de sant́e (KCE); 2006.
7. Bilcke J, Beutels P, De Smet F, et al. Cost-effectiveness analysis of rotavirus vaccination of Belgian infants. Heath Technology Assessment (HTA). KCE reports. Brussels: Belgian Health Care Knowledge Centre (KCE); 2007.
8. Boot HJ, Wallenburg I, de Melker HE, et al. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands. Vaccine. 2007;25:6245-6256. (Pubitemid 47096668)
9. Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: The impact of herd-immunity. Med Decis Making. 2003;23:76-82. (Pubitemid 36133362)
10. Brisson M, Van de Velde N, De Wals P, Boily M-C. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine. 2007;25:5399-5408. (Pubitemid 46977529)
11. Center for Biologics Evaluation and Research (CBER). Vaccines and Related Biological Products Advisory Committee - May, 18, 2006. GardasilTM : Quadrivalent Human Papillomavirus 6, 11, 16, 18 L1 VLP Vaccine. (Slide show by N. Miller). Rockville, MD: US Food and Drug Administration; 2006.
12. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis. 2008;14:244-251. (Pubitemid 351213674)
13. Cleemput I. Measuring self-reported health: An international perspective based on EQ-5D. Budapest: SpringMed Publishing; 2004.
14. Cleemput I, Van Wilder P, Vrijens F, Huybrechts M, Ramaekers D. Guidelines for pharmaco-economic evaluations in Belgium. Health Technology Assessment (HTA). In: F.K.v.d.G. (KCE), editor. KCE Reports. Brussels: Belgian Health Care Knowledge Centre (KCE); 2008.
15. Conseil Supérieur dela Santé-Hoge Gezondheidsraad. Vaccination contre les infections causées par le papillomavirus humain. Bruxelles: Service Public Fédéral-Santé Publique; 2007:34.
16. DanishCentre for Health Technology Assessment. Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV)-a health technology assessment. Copenhagen: Danish Centre for Health Technology Assessment; 2007.
17. Day N, Moss S, Berrino F, Choi N, Clarke E. Screening for squamous cervical cancer: Duration of low risk after negative results of cervical cytology and its implication for screening policies. IARCWorking Group on evaluation of cervical cancer screening programmes. Br Med J (Clin Res Ed). 1986;293:659-664.
18. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:28-41. (Pubitemid 46057835)
19. Fraser C, Tomassini JE, Xi L, et al. Modeling the long-term antibody response of a human papillomavirus (HPV) viruslike particle (VLP) type 16 prophylactic vaccine. Vaccine. 2007;25:4324-4333. (Pubitemid 46635934)
20. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-1927. (Pubitemid 46740302)
21. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-1943. (Pubitemid 46740303)
22. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604-615. (Pubitemid 38584984)
23. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women:Arandomised controlled trial. Lancet. 2004;364:1757-1765. (Pubitemid 39488060)
24. Hulstaert F, Arbyn M, Huybrechts M, et al. Cervical cancer screening and human papillomavirus (HPV) testing. KCE reports 38C. Brussels: Belgian Health Care Knowledge Centre (KCE); 2006.
25. InternationalAgency for Research on Cancer, World Health Organization. Cervix cancer screening. Lyon: IARC Press; 2005.
26. Kulasingam S, Connelly L, Conway E, et al. A costeffectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health. 2007;4:165-175. (Pubitemid 47339645)
27. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290:781-789.
28. McCrory DC, Matchar DB, Bastian L, et al. Evaluation of cervical cytology. Evid Rep Technol Assess (Summ). 1999:1-6.
29. Meijer CJ, Snijders PJ, Van Den Bruel AJ. Screening for cervical cancer: Should we test for infection with high-risk HPV? CMAJ. 2000;163:535-538. (Pubitemid 30742938)
30. Merck Research Laboratories. Updated efficacy data: Gardasil®. Presentation to the American Advisory Committee on Immunization Practices (ACIP), National Immunization Program (NIP), from the Center for Diseases Control (CDC) (Slide show by E. Barr). Atlanta: CDC; 2007.
31. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278-285. (Pubitemid 38924707)
32. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151:1158-1171. (Pubitemid 30451948)
33. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: A systematic review. Ann Intern Med. 2000;132:810-819. (Pubitemid 30317797)
34. Neilson A, Freisleben de Blasio B. Økonomisk evaluering av humant papillomavirus (HPV) vaksinasjon i Norge. Oslo: Nasjonalt kunnskapssenter for helsetjenesten (NOKC); 2007.
35. Newall AT, Beutels P,Wood JG, Edmunds WJ, MacIntyre CR. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis. 2007;7:289-296. (Pubitemid 46414076)
36. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9:37-48. (Pubitemid 36110201)
37. Sigurdsson K, Taddeo F, Benediktsdottir K, et al. HPV genotypes in CIN 2-3 lesions and cervical cancer: A populationbased study. Int J Cancer. 2007;121:2682-2687. (Pubitemid 350136412)
38. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer. 2007;121:621-632. (Pubitemid 46986496)
39. Stoykova B. HPV testing matters-Findings from a time tradeoff survey in England. Copenhagen: iHEA World Conference; 2007.
40. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10:1915-1923.
41. Thiry N, Lambert ML, Cleemput I, et al. HPV Vaccination for the prevention of cervical cancer in Belgium: Health technology assessment. Brussels: Belgian Health Care Knowledge Centre (KCE); 2007.
42. Van Damme P, Theeten H, Hoppenbrouwers K, et al. Studie van de vaccinatiegraad bij jonge kinderen en adolescenten in Vlaanderen in 2005. Brussels: Ministerie van de Vlaamse Gemeenschap. DepartementWelzijn, Volksgezondheid en Cultuur Administratie Gezondheidszorg; 2006:87.
43. van Eycken L, De Wever N. Cancer incidence and survival in Flandres, 2000-2001. Brussels: Flemish Cancer Registry Network, VLK; 2006.
44. van Oortmarssen GJ, Habbema JD, van Ballegooijen M. Predicting mortality from cervical cancer after negative smear test results. BMJ. 1992;305:449-451.
45. Villa LL, Costa RLR, Petta CA, et al. High sustained effi- cacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459-1466.
46. Woodman CBJ, Collins SI, Young LS. The natural history of cervical HPV infection: Unresolved issues. Nat Rev Cancer. 2007;7:11-22. (Pubitemid 46020844)